6 Houston-area inventors named fellows in prestigious program

best in class

Six Houston inventors have been recognized with the highest professional distinction for inventors within academia. Photo via Pexels

The National Academy of Inventors has announced its annual set of NAI Fellows — and six Houstonians make the list of the 164 honorees from 116 research institutions worldwide.

The NAI Fellows Program honors academic inventors "who have demonstrated a spirit of innovation in creating or facilitating outstanding inventions that have made a tangible impact on the quality of life, economic development, and the welfare of society," according to a news release. The appointment is the highest professional distinction for inventors within academia.

The six Houstonians on the list join a group that hold more than 48,000 U.S. patents, which have generated over 13,000 licensed technologies and companies, and created more than one million jobs, per the release. Additionally, $3 trillion in revenue has been generated based on NAI Fellow discoveries.

These are the scientists from Houston organizations:

    • Zhiqiang An, University of Texas Health Science Center at Houston: An is the director of the Texas Therapeutics Institute, a drug discovery program operated by the John P. and Kathrine G. McGovern Medical School at Houston. He's also a professor of molecular medicine and holder of the Robert A. Welch Distinguished University Chair in Chemistry at UTHealth.
    • Alex Ignatiev, University of Houston: Ignatiev served as director of two NASA-supported research and technology development centers at the University of Houston and as Lillie Cranz and Hugh Roy Cullen Professor of Physics, Chemistry, and Electrical and Computer Engineering.
    • David Jaffray, University of Texas MD Anderson Cancer Center: Jaffray was appointed MD Anderson's first-ever chief technology and digital officer in 2019. He oversees MD Anderson’s Information Services division and Information Security department and is a professor of Radiation Physics with a joint appointment in Imaging Physics.
    • Pei-Yong Shi,The University of Texas Medical Branch: Pei-Yong Shi is a professor and John Sealy Distinguished Chair in Innovations in Molecular Biology Department of Biochemistry & Molecular Biology;. He's also the Vice Chair for Innovation and Commercialization.
    • Ganesh Thakur, University of Houston: Thakur is a pioneer in carbon capture, utilization and storage and has a patent on forecasting performance of water injection and enhanced oil recovery. His team is continuing to push the research envelope for CCUS employing world-class lab research, simulation, machine learning and artificial intelligence.
    • Darren Woodside, Texas Heart Institute: Woodside is the Vice President for Research and Director of the Flow Cytometry and Imaging Core at the Texas Heart Institute. His research centers around the role that cell adhesion plays in cardiovascular and autoimmune diseases, and the development of novel means to identify and treat these diseases.
    Ten other Texas-based innovators made the list, including:
    • Sanjay Banerjee, The University of Texas at Austin
    • Thomas Boland, The University of Texas at El Paso
    • Joan Brennecke, The University of Texas at Austin
    • Gerard Cote, Texas A&M University
    • Ananth Dodabalapur, The University of Texas at Austin
    • Holloway (Holly) H. Frost Jr., The University of Texas at Arlington
    • James E. Hubbard, Texas A&M University
    • Yi Lu, University of Texas at Austin
    • Samuel Prien, Texas Tech University
    • Earl E. Swartzlander Jr., The University of Texas at Austin
    This year's class will be inducted at the Fellows Induction Ceremony at the 11th Annual Meeting of the National Academy of Inventors in June in Phoenix, Arizona.

    "The caliber of this year's class of NAI Fellows is outstanding. Each of these individuals are highly-regarded in their respective fields," says Paul R. Sanberg, president of NAI's board of directors, in the release. "The breadth and scope of their discovery is truly staggering. I'm excited not only see their work continue, but also to see their knowledge influence a new era of science, technology, and innovation worldwide."

    The five scientists represent five different academic institutions in Houston. Photo via Getty Images

    5 Houston inventors named fellows of a prestigious international program

    top researchers

    The National Academy of Inventors has recognized 175 scientists from across the world as NAI Fellows — and five of those inventors are based at Houston institutions.

    The program honors academic inventors who, according to NAI, "have demonstrated a spirit of innovation in creating or facilitating outstanding inventions that have made a tangible impact on quality of life, economic development and the welfare of society."

    The five Houston inventors join the ranks of a group of individuals who have generated over 13,000 licensed technologies and companies, and created more than 19 million jobs, according to the announcement.

    These are the scientists from Houston organizations:

    • Ananth Annapragada of Baylor College of Medicine is professor of radiology and obstetrics and gynecology, vice chief of research and director of basic research at Baylor College of Medicine and Texas Children's Hospital as well as a member of the Dan L Duncan Comprehensive Cancer Center.
    • Ronald Biediger of the Texas Heart Institute is associate director of chemistry, Wafic Said Molecular Cardiology Research Laboratories and leading a group of chemists developing small molecule integrin antagonists and agonists for use as therapies, or as adjuncts to cell based therapies, for heart, lung and vascular disease
    • Mark Clarke of the University of Houston is associate provost for faculty development and faculty affairs at the University of Houston.
    • Ashutosh Sabharwal of Rice University is professor and Ph.D of electrical engineering and was named Fellow of the Institute of Electrical and Electronics Engineers in 2014 for contributions to the theory and experimentation of wireless systems and networks.
    • Jia Zhou of The University of Texas Medical Branch is professor in the Department Pharmacology and Toxicology focusing on drug discovery of bioactive molecules to probe biological systems or act as potential therapeutic agents in neuroscience, cancer/inflammation, infectious diseases, and other human conditions.

    The new class of inventors will be inducted on June 8 at the 10th Annual Meeting of the National Academy of Inventors in Tampa, Florida.

    These scientists have already established dozens of patents between the five of them across fields and industries. Clarke specifically holds 13 U.S. patents, seven NASA technology innovation awards, and has founded two life science startup companies to commercialize his technologies, according to a news release from UH.

    "Most faculty inventors, including myself, do not begin their research careers focused on creating or commercializing new technologies, nor do they usually know where to start when presented with such an opportunity," Clarke says in the release. "Helping faculty members and students transition fundamental discoveries into commercially valuable technologies and products is not only a key part of our mission as a Tier One research university, it is critical to our region's economic prosperity and ensuring that the U.S. remains competitive in an innovation-driven global economy."

    From BCM, Annapragada holds 15 patents in the United States and close to 100 worldwide. The majority of his patents are in next generation imaging technologies, CT vascular imaging, and MR molecular imaging, according to a BCM release, and Annapragada is the founder of two active startup companies — Alzeca Inc. and Sensulin LLC.

    Ad Placement 300x100
    Ad Placement 300x600

    CultureMap Emails are Awesome

    Property Showcase

    4 Houston health tech startups advancing medical innovation

    meet the finalists

    Houston has been driving medical innovation for decades. And thanks to leading hospitals, cutting-edge research and breakthrough technologies, the region’s healthcare ecosystem continues to improve how patients are diagnosed, treated and cared for.

    The Health Tech Business category in our 2025 Houston Innovation Awards will honor an innovative startup within the health and medical technology sectors.

    Four forward-thinking businesses have been named finalists for the 2026 award. This year's finalists, selected by our esteemed panel of judges, range from a startup developing miniaturized medical technologies for space to a company using AI to help develop cancer treatment plans.

    Read more about these businesses, their innovative founders, and how they're shaping the future of health care below.. The 2026 winners will be announced on InnovationMap.com in mid-November.

    Bairitone Health

    Bairitone Health is bringing anatomy imaging for sleep apnea to the home environment. The company's platform maps users' anatomy during natural sleep using a facial patch to determine the root cause of airway obstruction. It then offers effective therapies for each patient.

    The company was founded in 2022 in the Texas Medical Center's Biodesign program by CEO Meagan Pitcher, CTO Onur Kilic and chief medical officer Britt Cross. It was a member of Activate Houston's inaugural cohort and has participated in numerous accelerators and incubators. The company raised an oversubscribed seed round for $2.4 million earlier this year and received Breakthrough Device Designation from the Food and Drug Administration in April.

    InformAI Inc.

    InformAI Inc. develops fit-to-purpose AI solutions for the clinical setting. Its RadOncAI product recently received FDA 510(k) clearance. The product uses AI to create a first-pass radiation therapy dose plan for complex head and neck cancers in an effort to eliminate bottlenecks in radiation planning and ultimately cancer treatment. The company has also developed AI products for sinus disease detection and 3D organ reconstruction.

    CEO Jim Havelka founded the company in 2017. It is participating in the Mayo Clinic Accelerate Platform. It has raised about $4 million in seed funding and has received numerous non-dilutive grants from the National Science Foundation, the National Institutes of Health and the Cancer Prevention and Research Institute of Texas. The company shared in its application that it plans to launch a Series A fundraising round and submit an FDA 510K application for its organ reconstruction product, Voluquant, by the end of 2026.

    Prana Surgical

    Prana Surgical is developing a minimally invasive surgical platform for small, hard-to-reach lung nodules that may be cancerous. The company's Prana System cleared U.S. Food and Drug Administration (FDA) approval earlier this year.

    Prana Surgical was originally founded as Prana Thoracic in 2022. It has participated in numerous accelerators, including the Texas Medical Center Innovation Accelerator in 2023 and the IGNITE Health accelerator in 2022. It raised $6 million in Series A funding rounds in 2023 and 2024 , with a Series B currently ongoing. The company said in its application that it is currently moving into the next stage of clinical validation and revenue generation in the U.S., in addition to preparing its manufacturing and commercial infrastructure for broader use.

    Skybound MedTech

    Skybound MedTech develops technologies that aim to address the health risks of long-duration spaceflight. Its compact, miniaturized medical technologies can deliver complex therapies without a physician.

    CEO Matthew Kuhn, who previously founded Taurus Vascular, founded Skybound last year. The company emerged from stealth in January after raising a $1.25 million Series A round. It plans to advance its lead dual-use platform into critical preclinical validation in November, the company shared in its application. It is currently raising a $25 million Series A round and is pursuing federal research partnerships with DARPA and ARPA-H.

    Generation Park lands new facility to scale xeno-organ production

    Organ innovation

    Maryland-based United Therapeutics Corp. has opened a new 77,448-square-foot facility to manufacture xeno-organs in Northeast Houston’s growing biotech hub, Generation Park.

    The new Houston location is United Therapeutics’ third Designated Pathogen-Free (DPF) site, named for transplant pioneers Dr. Bartley P. Griffith and Dr. Robert A. Montgomery. The company says the new facility will enable it to scale commercial production of its xeno-organs once they receive regulatory approval.

    An existing DPF facility in Virginia is supporting clinical trials for the xeno-organs, and a third site in Minnesota will also focus on commercialization with the Houston site, according to the company.

    Xeno-organs are organs taken from a non-human animal source and transplanted, implanted or infused into a human recipient.

    Currently, United Therapeutics is advancing clinical trials to support a Biologics License Application with the U.S. Food and Drug Administration for its investigational-stage xenotransplantation, UKidney, UThymoKidney and UHeart products. The products all involve working with the genes from humans and pigs.

    In 2025, Chron.com reported the company was working to construct an estimated $96 million facility to breed genetically engineered animals. Head of investor relations at United Therapeutics Dewey Steadman told the Houston Business Journal in 2025 that the pigs’ DNA will be edited. In November 2024, a 53-year-old woman in Alabama received a transplanted kidney from UKidney that had 10 gene edits. She had the transplant removed in April 2025, after her body rejected it.

    The Dr. Bartley P. Griffith and Dr. Robert A. Montgomery Xenograft Production Facility requires a “strictly controlled, biosecure barrier environment, including air filtration, filtered water, filtered feed supplies, and state-of-the-art decontamination entryways,” according to the company. Being pathogen-free means it includes calibrated air and water conduits to support the transplantability of xenograft products and to prevent contamination. For energy considerations, the building also features solar arrays.

    “With our third xenograft production facility now open and clinical trials underway, United Therapeutics is moving closer to its goal of providing transplantable organs to the people who need them,” Martine Rothblatt, chairperson and CEO of United Therapeutics, said in a news release. “It is fitting that this facility is named for Dr. Griffith and Dr. Montgomery, whose first-in-human surgeries turned xenotransplantation from a theoretical possibility into a clinical reality.”

    The facility, which wrapped construction in August, is located at 11848 Common Dock Dr. in Generation Park, which will house manufacturing sites for pharmaceutical heavyweights Bristol Myers Squibb and Eli Lilly. Last fall, Eli Lilly tapped Generation Park for its $6.5 billion manufacturing plant, and Bristol Myers Squibb made a $2.3 billion investment in August to bring its state-of-the-art site to the master-planned commercial district.

    Elon Musk's SpaceX reports profit as AI and satellite businesses booms

    Booming Business

    SpaceX reported a bigger quarterly profit than expected on Tuesday, October 20, as its satellite communications and artificial intelligence businesses boomed.

    The company, run by Elon Musk, posted a profit for the three months through September 2026 of $4.4 billion, or 35 cents per share, reversing a year-ago loss and easily topping Wall Street's expectations. Revenue soared to $14.6 billion, up 161%.

    On a conference call with analysts, Musk suggested a merger with his electric car company Tesla might be in the works, something that has been rumored for months. He said both companies formed “special committees” of independent directors to discuss the issue, though he played down the chances of an imminent deal.

    “Some people out there assume that a SpaceX and Tesla merger is a certainty,” he said. “I think that would be overstating it.”

    The AI business became SpaceX's largest by revenue in the third quarter, although the Starlink satellite service remains the biggest profit generator.

    “They beat across all metrics and the Starlink business looks to be accelerating,” said Dan Ives, an analyst at Yorkville Ives. “This is just what (Wall) Street wanted.”

    The stock rose 7.5% in after-hours trading.

    Musk also told analysts that for next month's launch of its Starship rocket, SpaceX will attempt to grab both the booster and ship with mechanical arms upon return to base, a key step toward demonstrating it can reuse the massive spacecraft.

    “The only way that we can extend consciousness beyond Earth on a sustained basis is with a fully reusable orbital launch vehicle,” Musk said, calling the attempt, if successful, “a massive technology milestone.”

    SpaceX hopes to get Starship on a regular launch pattern in preparation for NASA's upcoming lunar missions.

    The company already has huge contracts with the federal government, and House Democrats have called for investigations into those contracts and Musk’s work with the Department of Government Efficiency. Musk has spent $276 million since July in support of Republican candidates.

    In a filing for its initial public offering in June, SpaceX warned that a change in control of Congress could have a “material and adverse impact on our growth and competitive position.”

    Musk recently drew criticism from politicians in Washington after speeds for a military version of SpaceX's satellite communications service were slowed for Ukraine following President Donald Trump's deal to get more diesel oil from Russia amid a push to end the war. The Wall Street Journal reported Tuesday that it was Musk who ordered the slowdown, impeding Ukraine’s use of drones along the front. SpaceX did not immediately respond to an Associated Press request for comment on the Journal story.

    Both Trump and Musk have denied responsibility for the slowdown.

    As midterm elections near, Musk on Monday promised to give one share of SpaceX to “every kid in America” next year, though he provided no details on how the distribution would be carried out. With communities nationwide protesting the construction of large data centers and concerns about AI safety, AI companies are trying to build goodwill. Anthropic pledged to commit 5% of its shares to a new “public benefit” fund.

    SpaceX shares have been under pressure over concerns that the company was spending too much on major projects to compete with rivals such as Anthropic. The company said capital expenditures totaled $19.6 billion last quarter, nearly triple the figure from a year earlier, and it forecast spending would grow to $35 billion to $40 billion in the current quarter.

    Shares of SpaceX closed Tuesday at $147.79, down from a peak near $201 after its IPO, which made Musk the world’s first trillionaire at the time. But the share prices for SpaceX and Tesla have since dropped, reducing his net worth to $925 billion, according to Forbes magazine.

    Tesla reports third-quarter financial results Wednesday. Last week, Tesla unveiled a new Roadster sports car that in some versions may include thrusters allowing it to briefly fly using SpaceX technology — though experts say anything usable for drivers is a long shot.

    View All Listings